EUCTR2009-011106-42-CZ进行中（未招募）不适用
Aditive effects of omega-3 polyunsaturated fatty acids and pioglitazone in the treatment of type 2 diabetes mellitus - MEPIO
Institute for Clinical and Experimental Medicine0 个研究点目标入组 60 人开始时间: 2009年5月26日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Type 2 diabetes mellitus as defined by the criteria of the American Diabetes Association and recognized by WHO, Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (American Diabetes Association, 2004) at least 3 months preceding screening
- •2. Concurrent T2DM therapy:
- •Taking metformin as a monotherapy at stable dose in at least 2 months preceding week 0 procedures
- •Previous chronic diabetes therapy will be limited to: sulfonylureas, glitinides, biguanides, ? glucosidase inhibitors such as acarbose, insulin.
- •3. HbA1c (IFCC): < 8 % (equals to aprox. 10% by DCCT), Triglycerides 2-6 mmol/l
- •4. Men and women who are 30 to 70 years of age
- •5. Body Mass Index between 25 and 45 (kg/m2)
- •6. Informed Consent: a signed and dated written consent obtained from the subject before any procedures are performed
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Metabolic Disease including:
- •Diagnosis of Type 1 diabetes mellitus
- •Uncorrected thyroid dysfunction. (NOTE: subjects with hypothyroidism on a stable dose of thyroid replacement therapy for at least 3 months prior to Screening, and who have a screening thyroid stimulating hormone (TSH) within the limits of normal may participate).
- •2.Significant weight gain or loss (as defined as > 5% of total body weight) within the past 3 months prior to Screening.
- •3.Regular use of insulin in previous 3 months
- •4.History of clinically significant cardiovascular disease including:
- •Documented myocardial infarction in the past year
- •Coronary revascularization including percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) surgery in the previous year and no subsequent angina
- •Unstable angina
- •Congestive heart failure (CHF) classified as New York Heart Association (NYHA) Class II, III or IV heart failure
- •5.Blood pressure > 150/100mmHg or HR > 100 beats/minute. Subjects using antihypertensives must be on stable doses during the 3 months prior to Screening and during the trial.
- •6.If a subject is receiving lipid-lowering therapy, then they must have been on the same dose of therapy for the past 3 months, concomitant fenofibrate therapy is not allowed and must be withdrawn at least 1 month ahead of week 0 procedures.
- •7.Is currently lactating, pregnant or actively trying to become pregnant.
- •8.Has a significant renal impairment as defined by serum creatinine > 150umol/L.
- •9.Has a documented history of chronic or advanced hepato-biliary disease including a history of, or positive laboratory results for hepatitis (hepatitis B surface antigen, hepatitis B core antigen, and hepatitis C antibody) at Screening.
- •Has clinically significant hepatic enzyme elevation greater than 2.5 times the upper limit of the reference range value /alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP) /
- •Has a total bilirubin level that is > 1.5 times the ULRR at Screening.
- •10.Has a history of alcohol or substance abuse within the past year
- •11.Is currently taking and will not stop prohibited concomitant medications, see concomitant therapy.
- •12.Known allergy to any of the capsule excipients, or history of drug or other allergy, which, in the opinion of the responsible study physician, contradicts participation.
- •13.Received treatment with an investigational drug or participated in any other clinical trial during the previous 3 months.
- •14.Clinically significant anemia (i.e., hemoglobin < 120.0g/L for males and < 110.0g/L for females) or any other abnormal hematological profile that is considered by the investigator to be clinically significant.
- •15.In the opinion of the Investigator has a risk of non-compliance with study procedures, or cannot read, understand, or complete study-related materials, particularly the informed consent.
- •16.Has any concurrent condition or any clinically significant abnormality identified on the screening physical examination, laboratory tests, electrocardiogram, including pulmonary, neurological or inflammatory diseases, which, in the opinion of the Investigator, may affect the interpretation of efficacy and safety data, or which otherwise, contraindicates participation in a clinical trial with the chemical entity.
研究者
相似试验
已完成
不适用
The influence of polyunsatturated omega-3-fattyacids on the onset of major cardiac events following a two year period after cardiac bypass procedureDRKS00000099Herzzentrum DresdenUniversitätsklinikKlinik f. Herzchirurgie151
已完成
2 期
The effect of omega 3 polyunsaturated fatty acid supplementation on inflammatory markers and insulin resistanse factors in patients with Type 2 Diabetes and Nonalcoholic Fatty Liver DiseaseCondition 1: type 2 diabetes. Condition 2: Nonalcoholic fatty liver disease (NAFLD).Non-insulin-dependent diabetes mellitusFatty (change of) liver, not elsewhere classified (NAFLD)IRCT2017103030489N2Yazd Shahid Sadoughi University of Medical Sciences48
已完成
2 期
Effect of omega-3 fatty acid supplementation in patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.Condition 1: type 2 diabetes. Condition 2: Nonalcoholic fatty liver disease (NAFLD).Non-insulin-dependent diabetes mellitusFatty (change of) liver, not elsewhere classified (NAFLD)IRCT2016102530489N1Yazd Shahid Sadoughi University of Medical Sciences60
已完成
不适用
The effect of omega-3 in the prevention of cardiac complications after PCIChronic ischaemic heart disease.Atherosclerotic heart diseaseIRCT2016072329035N1Ardabil University of Medical Sciences100
进行中（未招募）
1 期
The Effect of omega-3 polyunsaturated Fatty Acid Supplements on Microvolt T-Alternans in Patients with Ventricular ArrythmiaEUCTR2005-002688-10-GBniversity of Dundee